Evidence map›Paper›PMID 28419165›Full record

ArticlePloS one2017

Soaking suggests "alternative facts": Only co-crystallization discloses major ligand-induced interface rearrangements of a homodimeric tRNA-binding protein indicating a novel mode-of-inhibition.

Frederik Rainer Ehrmann, Johann Stojko, Alexander Metz, François Debaene, Luzi Jakob Barandun, Andreas Heine, François Diederich, Sarah Cianférani, Klaus Reuter, Gerhard Klebe

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Prediction of enzyme inhibition (ICJournal of molecular modeling · 2025
    Article
  3. Article
  4. Virtual screening: hope, hype, and the fine line in between.Expert opinion on drug discovery · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. FragMAX: the fragment-screening platform at the MAX IV Laboratory.Acta crystallographica. Section D, Structural biology · 2020
    Article
  14. Article
  15. Protein X-ray Crystallography and Drug Discovery.Molecules (Basel, Switzerland) · 2020
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Frederik Rainer EhrmannInstitut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marburg, Germany.
Johann StojkoLaboratoire de Spectrométrie de Masse Bio-Organique, Université de Strasbourg, CNRS, IPHC UMR 7178, Strasbourg, France.
Alexander MetzInstitut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marburg, Germany.
François DebaeneLaboratoire de Spectrométrie de Masse Bio-Organique, Université de Strasbourg, CNRS, IPHC UMR 7178, Strasbourg, France.
Luzi Jakob BarandunLaboratorium für Organische Chemie, ETH Zurich, Zurich, Switzerland.
Andreas HeineInstitut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marburg, Germany.
François DiederichLaboratorium für Organische Chemie, ETH Zurich, Zurich, Switzerland.
Sarah CianféraniLaboratoire de Spectrométrie de Masse Bio-Organique, Université de Strasbourg, CNRS, IPHC UMR 7178, Strasbourg, France.
Klaus ReuterInstitut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marburg, Germany.
Gerhard KlebeInstitut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marburg, Germany.ORCID http://orcid.org/0000-0002-4913-390X
Philipps University of Marburg · DECentre National de la Recherche Scientifique · FRETH Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For the efficient pathogenesis of Shigella, the causative agent of bacillary dysentery, full functionality of tRNA-guanine transglycosylase (TGT) is mandatory. TGT performs post-transcriptional modifications of tRNAs in the anticodon loop taking impact on virulence development. This suggests TGT as a putative target for selective anti-shigellosis drug therapy. Since bacterial TGT is only functional as homodimer, its activity can be inhibited either by blocking its active site or by preventing dimerization. Recently, we discovered that in some crystal structures obtained by soaking the full conformational adaptation most likely induced in solution upon ligand binding is not displayed. Thus, soaked structures may be misleading and suggest irrelevant binding modes. Accordingly, we re-investigated these complexes by co-crystallization. The obtained structures revealed large conformational rearrangements not visible in the soaked complexes. They result from spatial perturbations in the ribose-34/phosphate-35 recognition pocket and, consequently, an extended loop-helix motif required to prevent access of water molecules into the dimer interface loses its geometric integrity. Thermodynamic profiles of ligand binding in solution indicate favorable entropic contributions to complex formation when large conformational adaptations in the dimer interface are involved. Native MS titration experiments reveal the extent to which the homodimer is destabilized in the presence of each inhibitor. Unexpectedly, one ligand causes a complete rearrangement of subunit packing within the homodimer, never observed in any other TGT crystal structure before. Likely, this novel twisted dimer is catalytically inactive and, therefore, suggests that stabilizing this non-productive subunit arrangement may be used as a further strategy for TGT inhibition.

Indexed as

Models, MolecularProtein MultimerizationBacterial ProteinsCatalytic DomainCrystallizationCrystallography, X-RayEnzyme InhibitorsHydrophobic and Hydrophilic InteractionsLigandsPentosyltransferasesProtein BindingProtein ConformationProtein DomainsProtein StabilityProtein Structure, SecondaryRNA, TransferBacterial ProteinsEnzyme InhibitorsLigandsPentosyltransferasesqueuine tRNA-ribosyltransferaseRNA, TransferSolutions

Identifiers

PMID28419165
PMCPMC5395182
OpenAlexW2605915778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.